International journal of psychiatry in clinical practice · 2026
The impact of the COVID-19 pandemic on mental health symptoms in new patients presenting to outpatient psychiatry.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Swanson Leslie M, Bommarito Sarah, Kile Kristina, Warren Ricks, Montalva Roen, Bullard Katherine H, McCabe Vita V, Patel Paresh D, Dalack Gregory W
Аннотация
OBJECTIVE: To compare self-reported anxiety, depression, insomnia, functional impairment, and substance use among distinct cohorts of new adult psychiatric outpatients before and after the onset of the COVID-19 pandemic.
METHODS: Outpatient intake visit data, collected pre-pandemic (May 1, 2019-February 28, 2020) and early in the pandemic (May 1, 2020-February 26, 2021), included the Generalised Anxiety Disorder-7 (GAD-7), Patient Health Questionnaire-9 (PHQ-9), Insomnia Severity Index (ISI), Work and Social Adjustment Scale (WSAS), and the World Health Organisation Alcohol, Smoking, and Substance Involvement Screening Test. Substance use treatment-seeking patients also completed the Brief Addiction Monitor. Analysis of variance models, adjusted for sex and race, examined between-cohort differences.
RESULTS: Among 4,197 patients (pre-pandemic: 2,434; early pandemic: 1,763), anxiety and insomnia (GAD-7, ISI) symptoms were greater after pandemic onset. Depression (PHQ-9) and functioning (WSAS) were not different. Rates of cannabis, cocaine, and inhalant use were higher post-pandemic. Among substance use treatment seekers, drug and marijuana use was higher, with women reporting more binge drinking days.
CONCLUSIONS: New psychiatric outpatients who presented after the pandemic reported greater anxiety and insomnia symptoms and different substance use patterns vs. a pre-pandemic cohort, underscoring the need for targeted interventions during public health crises.
METHODS: Outpatient intake visit data, collected pre-pandemic (May 1, 2019-February 28, 2020) and early in the pandemic (May 1, 2020-February 26, 2021), included the Generalised Anxiety Disorder-7 (GAD-7), Patient Health Questionnaire-9 (PHQ-9), Insomnia Severity Index (ISI), Work and Social Adjustment Scale (WSAS), and the World Health Organisation Alcohol, Smoking, and Substance Involvement Screening Test. Substance use treatment-seeking patients also completed the Brief Addiction Monitor. Analysis of variance models, adjusted for sex and race, examined between-cohort differences.
RESULTS: Among 4,197 patients (pre-pandemic: 2,434; early pandemic: 1,763), anxiety and insomnia (GAD-7, ISI) symptoms were greater after pandemic onset. Depression (PHQ-9) and functioning (WSAS) were not different. Rates of cannabis, cocaine, and inhalant use were higher post-pandemic. Among substance use treatment seekers, drug and marijuana use was higher, with women reporting more binge drinking days.
CONCLUSIONS: New psychiatric outpatients who presented after the pandemic reported greater anxiety and insomnia symptoms and different substance use patterns vs. a pre-pandemic cohort, underscoring the need for targeted interventions during public health crises.